Abstract
Retroviral suicide gene vectors have successfully been used in clinical studies to improve the safety of adoptive immunotherapy with allogeneic T lymphocytes in the treatment of malignant and viral diseases. At the same time these studies have revealed several problems that are yet to be resolved including impaired T cell function due to long ex vivo culture. Here we present new retroviral vectors co-expressing truncated CD34, a gene transfer marker which ensures rapid enrichment of transduced cells using commercially available GMP-approved devices, and a splice-corrected variant of Herpes simplex virus thymidine kinase (scHSVtk) which confers high sensitivity to the prodrug ganciclovir. We show that a retroviral hybrid vector, MP71, based on the myeloproliferative sarcoma virus (MPSV) and the murine embryonic stem cell virus (MESV), encoding a tCD34/scHSVtk fusion protein mediates high expression of the ‘sort-suicide’ selection marker, thereby allowing for highly efficient purification and selective elimination of transduced cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kolb HJ et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients Blood 1990 76: 2462–2465
Slavin S et al. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines Cancer Invest 1992 10: 221–227
Riddell S et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones Science 1992 257: 238–241
Papadopoulos ED et al. Infusion of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation N Engl J Med 1994 330: 1185–1191
Barrett AJ, Malkovska V . Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematogical malignancies Br J Haematol 1996 93: 754–761
Fehse B et al. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69) Br J Haematol 2000 109: 644–651
Tiberghien P et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994 84: 1333–1341
Bonini C et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus leukemia Science 1997 276: 1719–1724
Champlin R et al. Phase I/II study of thymidine kinase (TK)-transduced donor lymphocyte infusion (DLI) in patients with hematologic malignancies Blood 1999 94: 324a
Tiberghien P et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft Blood 2001 97: 63–72
Sauce D et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms Blood 2002 99: 1165–1173
Ayuk FA, Zander AR, Fehse B . T lymphocytes as targets of gene transfer with Moloney type retroviral vectors Curr Gene Ther 2001 1: 325–337
Chalmers D et al. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene Mol Ther 2001 4: 146–148
Drobyski WR, Majewski D, Ozker K, Hanson G . Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease, but retain their ability to facilitate alloengraftment J Immunol 1998 161: 2610–2619
Contassot E et al. In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes Transplantation 1998 65: 1365–1370
Ferrand C et al. Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire Hum Gene Ther 2000 11: 1151–1164
Weijtens M et al. Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats Hum Gene Ther 2002 13: 187–198
Fehse B et al. CD34 splice variant: an attractive marker for selection of gene-modified cells Mol Ther 2000 1: 448–456
Baum C et al. Novel retroviral vectors for efficient expression of the multidrug-resistance (mdr-1) gene in early hemopoietic cells J Virol 1995 69: 7541–7547
Hildinger M, Abel KL, Ostertag W, Baum C . Design of 5’ untranslated sequences in retroviral vectors developed for medical use J Virol 1999 73: 4083–4089
Kaminski A, Howell MT, Jackson RJ . Initiation of encephalomyocarditis virus RNA translation: the authentic initiation site is not selected by a scanning mechanism EMBO J 1990 9: 3753–3759
Beyer WR, Westphal M, Ostertag W, von Laer D . Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range J Virol 2002 76: 1488–1495
Wahlers A et al. Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells Gene Therapy 2001 8: 477–486
Ayuk F et al. Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements Gene Therapy 1999 6: 1788–1792
Fehse B et al. Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin (FN) Br J Haematol 1998 102: 566–574
Mizuguchi H et al. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector Mol Ther 2000 1: 376–382
Schwartz F et al. A dominant positive and negative selectable gene for use in mammalian cells Proc Natl Acad Sci USA 1991 88: 10416–10420
Degrève B et al. Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK J Virol 1998 72: 9535–9543
Degrève B, Esnouf R, De Clercq E, Balzarini J . Characterization of multiple nuclear localization signals in herpes simplex virus type 1 thymidine kinase Biochem Biophys Res Commun 1999 264: 338–342
Kühlcke K et al. Highly efficient retroviral gene transfer based on centrifugation-mediated vector pre-loading of tissue culture vessels Mol Ther 2002 5: 473–478
Li Z . Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cell Leukemia 2002 16: 1655–1663
Acknowledgements
The authors wish to thank Dung Ung and Melanie Engel for excellent technical assistance, as well as the blood bank of the University Hospital Eppendorf for kind cooperation. We are indebted to Francis Ayuk for critical reading of the manuscript. This work was supported by the European Community (QLK3-2001-01265). AW is supported by the Deutsches Krebsforschungszentrum (Ca 97).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fehse, B., Kustikova, O., Li, Z. et al. A novel ‘sort-suicide’ fusion gene vector for T cell manipulation. Gene Ther 9, 1633–1638 (2002). https://doi.org/10.1038/sj.gt.3301828
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301828
Keywords
This article is cited by
-
Retroviral gene therapy in Germany with a view on previous experience and future perspectives
Gene Therapy (2021)
-
Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept
Gene Therapy (2015)
-
In Vivo Proof of Concept of Adoptive Immunotherapy for Hepatocellular Carcinoma Using Allogeneic Suicide Gene-modified Killer Cells
Molecular Therapy (2014)
-
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial
Cancer Immunology, Immunotherapy (2014)
-
An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T Cells for Adoptive Immunotherapy
Molecular Therapy (2010)